GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will be included in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017.

The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals, which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.

For more information about the NBI, please see https://indexes.nasdaqomx.com/Index/Overview/NBI.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' first drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, a specific E-selectin antagonist, has been evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in an ongoing Phase 1 clinical trial for the treatment of multiple myeloma. The U.S. Food and Drug Administration has granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also conducted a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005277/en/